Acrivon Therapeutics, Inc.

Listed Company

ACRVCIK 0001781174NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-77.90M

Total Assets

$129.72M

Equity

$112.52M

Shares Out

38.74M

Op. Cash Flow

$-63.66M

Business

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing precision oncology medicines using its proprietary Generative Phosphoproteomics platform, AP3. Its primary offerings include internally discovered and in‑licensed drug candidates (notably ACR‑368 and ACR‑2316), AP3-enabled preclinical programs, and drug‑tailored OncoSignature companion diagnostic tests. The company operates through integrated drug discovery, preclinical optimization, clinical development and companion diagnostic co‑development segments, supported by partnerships and licensing arrangements. It advances multi‑center clinical trials in the United States and leverages third‑party manufacturers and diagnostic partners for testing and distribution.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	60	64	46	24	—
General and administrative	24	25	21	9	—
Total operating expenses	84	89	67	33	16
Loss from operations	−84	−89	−67	−33	−16
Interest income	6	9	7	—	—
Other expense, net	−270,000	−558,000	−322,000	2	21,000
Total other income, net	6	9	7	1	−59,000
Net loss	−78	−81	−60	−31	−16
Net loss per sharebasic	−2.02	−2.38	−2.74	−7.56	−9.32
Net loss per sharediluted	−2.02	−2.38	−2.74	−7.56	−9.32
Weighted-average common stock outstandingbasic	39	34	22	4	2
Weighted-average common stock outstandingdiluted	39	34	22	4	2
Unrealized (loss) gain on available-for-sale investments, net of tax	−336,000	530,000	12,000	−95,000	—
Comprehensive loss	−78	−80	−60	−31	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	41	40	36	30	100
Short-term investments	77	140	91	98	—
Prepaid expenses and other current assets	2	2	2	4	805,000
Total current assets	120	182	130	132	100
Property and equipment, net	5	4	3	2	290,000
Operating lease right-of-use assets	3	4	4	5	6
Long-term investments	—	5	—	42	—
Restricted cash	203,000	198,000	414,000	388,000	388,000
Other assets	2	2	251,000	—	—
Total assets	130	197	138	181	107
Accounts payable	2	758,000	5	904,000	964,000
Accrued expenses and other current liabilities	12	15	7	5	1
Operating lease liabilities, current	1	1	877,000	726,000	664,000
Total current liabilities	16	17	13	7	3
Operating lease liabilities, non-current	2	3	4	4	5
Total liabilities	17	20	17	11	8
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2025 and 2024; 31,648,856 and 31,231,264 shares issued and outstanding as of December 31, 2025 and 2024, respectively	31,000	31,000	23,000	22,000	2,000
Additional paid-in capital	387	373	238	227	1
Accumulated other comprehensive income	111,000	447,000	−83,000	−95,000	—
Accumulated deficit	−275	−197	−116	−56	−25
Total stockholders' equity	113	177	121	170	−24
Total liabilities and stockholders' equity	130	197	138	181	107

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−78	−81	−60	−31	−16
Depreciation expense	1	1	500,000	400,000	37,000
Stock-based compensation expense	15	14	12	2	497,000
Non-cash operating lease expense	1	932,000	778,000	—	—
Net amortization of premiums and accretion of discounts on investments	−437,000	−4	−3	−698,000	—
Prepaid expenses and other current assets	190,000	237,000	2	−4	−764,000
Accounts payable	2	−4	4	−245,000	798,000
Accrued expenses and other liabilities	−3	8	3	3	866,000
Operating lease liabilities	−936,000	−1	−754,000	−667,000	−572,000
Other assets	137,000	−1	—	—	—
Net cash used in operating activities	−64	−66	−43	−30	−14
Purchases of investments	−82	−203	−57	−150	—
Proceeds from maturities of investments	150	154	109	11	—
Purchases of property and equipment	−2	−3	−1	−2	−238,000
Net cash provided by (used in) investing activities	66	−52	51	−142	−238,000
Proceeds from issuance of common stock in private placement	—	70	—	5	—
Proceeds from issuance of pre-funded warrants in private placement	—	60	—	—	—
Proceeds from exercise of stock options	1,000	90,000	775,000	24,000	1,000
Payments of offering costs	—	−7	−1	−3	—
Payments of tax withholdings related to vesting of restricted stock units	−750,000	−3	−1	—	—
Net cash (used in) provided by financing activities	−749,000	121	−2	102	112
Net increase in cash, cash equivalents, and restricted cash	2	4	7	−70	98
Deferred offering costs in accrued expenses and other current liabilities	143,000	—	—	—	—
Purchases of property and equipment included in accounts payable	—	17,000	635,000	—	30,000
Right-of-use assets obtained in exchange for operating lease liability	—	56,000	437,000	—	6

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro